Triple-Negative Breast Cancer | Topics

 
FDA Issues Complete Response Letter for Pembrolizumab as Neoadjuvant Therapy in Early TNBC
March 30, 2021

The FDA’s Oncologic Drugs Advisory Committee voted in favor of waiting for additional event-free survival data to become available before making a regulatory decision regarding a biologics license application for pembrolizumab in early triple-negative breast cancer.

Further Data Necessary to Gauge Value of Immune Checkpoint Inhibitors to Treat Patients With Early-Stage TNBC
March 07, 2021

Adam Brufsky, MD, PhD, presented data investigating immunotherapeutic options in the neoadjuvant setting for patients with triple-negative breast cancer.

Tumor Cell Expression of PD-L1 is Key in Predicting Efficacy of Pembrolizumab for Patients With mTNBC
March 05, 2021

The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.